Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共2页
• 作者

  Fischer M.; Wulff B.; Baruchel S.; Berlanga P.; Trahair T.; Mechinaud F.; Schulte J.; Modak S.; Merks J. H.; Zwaan C. M.; Marshall L. V.; Casanova M.; Branle F.; Malet I.; Emeremni A. C.; Geoerger B.;

  展开▼
• 作者单位

  Univ Childrens Hosp Cologne Pediat Oncol Cologne Germany;

  Univ Childrens Hosp III Pediat Hematol &

  Oncol Essen Germany;

  Hosp Sick Children Hematol &

  Oncol Toronto ON Canada;

  Hosp La Fe Pediat Oncol Unit Valencia Spain;

  Sydney Childrens Hosp Kids Canc Ctr Randwick NSW Australia;

  Royal Childrens Hosp Melbourne Children Canc Ctr Melbourne Vic Australia;

  Charite Pediat Hematol Oncol &

  Stem Cell Transplantat Berlin Germany;

  Mem Sloan Kettering Canc Ctr Pediat 1275 York Ave New York NY 10021 USA;

  Emma Childrens Hosp Acad Med Ctr Pediat Oncol Amsterdam Netherlands;

  Sophia Childrens Univ Hosp Erasmus MC Pediat Oncol Rotterdam Netherlands;

  Royal Marsden NHS Fdn Trust London England;

  Fdn IRCCS Ist Nazl Tumori Pediat Oncol Milan Italy;

  Novartis Pharma AG Oncol Clin Dev Basel Switzerland;

  Novartis Pharma AG Oncol Clin Dev Basel Switzerland;

  Novartis Pharmaceut Coporat Biometr &

  Data Management E Hanover NJ USA;

  Gustave Roussy Pediat &

  Adolescent Oncol Villejuif France;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词